Genetic medicine specialist Lexeo Therapeutics is the latest biotech to line up an initial public offering (IPO), aiming to raise around $100 million from the transaction.
Shares in the company – of which around nine million have been issued at $11 apiece – are due to start trading on the Nasdaq later today under the LXEO ticker.
